Skip to content
Clinical Trials – home

Biotin: A Versatile Vitamin in Medical Research

4 / 4
trials open to patients / all trials
3+
Countries

In short

Biotin, also known as vitamin B7, is being studied in clinical trials for its potential benefits in various medical conditions. These trials aim to investigate biotin's effects on red blood cell survival, anemia, multiple sclerosis, Huntington's disease, and cancer detection. Researchers are exploring different applications of biotin, from its use as a marker in blood cells to its potential therapeutic effects when combined with other substances.

What is Biotin?

Biotin, also known as vitamin B7, is a naturally occurring vitamin that plays an important role in various bodily functions. It is being studied for its potential benefits in treating different medical conditions. Biotin is sometimes referred to as "vitamin H" in some research contexts.

Medical Uses of Biotin

Biotin is being investigated for its potential therapeutic effects in several medical conditions:

  • Multiple Sclerosis (MS): High-dose biotin is being studied as a treatment option for progressive forms of MS. It may help improve symptoms and slow disease progression.
  • Huntington's Disease: Researchers are exploring the combined use of biotin and thiamine (another B vitamin) in patients with Huntington's disease. This combination therapy may help modify the disease course or prevent symptom progression in early stages.
  • Asthma: Biotin is being investigated as a potential adjunctive (add-on) therapy for children with moderate persistent asthma. It may help improve lung function and asthma control.

Research Applications

Biotin is also used as a research tool in medical studies:

  • Red Blood Cell (RBC) Survival Studies: Biotin is used to label red blood cells, allowing researchers to track their lifespan in the body. This technique is being applied to study various conditions, including:
    • Sickle Cell Disease: To understand how long RBCs survive in people with and without sickle cell disease.
    • Diabetes: To measure RBC lifespan in diabetic children and compare it to non-diabetic individuals.
    • Anemia: To investigate possible causes of unexplained anemia in older people.

Safety and Side Effects

While biotin is generally considered safe, researchers are closely monitoring its effects, especially when used in high doses or for extended periods:

  • In some studies, a small number of participants developed antibodies (immune system proteins) against biotin-labeled RBCs. These antibodies were typically temporary and lasted up to 12 months.
  • Ongoing studies are evaluating the safety and tolerability of high-dose biotin in various patient populations.

Ongoing Research

Several clinical trials are currently underway to further investigate the potential benefits and applications of biotin:

  • A study is examining whether high-dose biotin increases clinical inflammatory activity in patients with progressive forms of MS.
  • Researchers are exploring the combined use of biotin and thiamine in Huntington's disease, with the goal of potentially modifying disease progression.
  • A trial is investigating the safety and tolerability of high-dose biotin in patients with Amyotrophic Lateral Sclerosis (ALS), a progressive neurological disease.
  • Scientists are studying the efficacy and safety of biotin as an adjunctive therapy in children with moderate persistent asthma.

Questions people often ask

Conditions where Biotin is being studied

Each condition opens its own overview and trial list

Trials with Biotin

Recruiting trials first

See all 4 →
Quick filters
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).